As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tevogen Inc. The largest reported stake is Saadi Ryan H.'s, at 91.1%. 6 filings are on record since July 25, 2025 (Schedule 13D/A, November 4, 2026).
Sell to companies like Tevogen Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Saadi Ryan H. · Sole voting: 61,705,689 · Shared voting: 3,878 · Sole dispositive: 1,938,710 · Shared dispositive: 3,878 · SCHEDULE 13D/A, 2026-11-04
- · Reporting person: Kirti Desai · Sole voting: 992,983 · Shared voting: 0 · Sole dispositive: 187,983 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-16
- · Holder: Saadi Ryan H. · Percent: 74.4% · SCHEDULE 13D/A
- · Holder: Saadi Ryan H. · Percent: 59.7% · SCHEDULE 13D/A
- · Holder: Ryan H. Saadi · Percent: 62% · SCHEDULE 13D/A
Tevogen Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-25. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 91.1% | 61,709,567 | SCHEDULE 13D/A, 2026-11-04 | 2026-11-02 | |
| 6.3% | 992,983 | SCHEDULE 13D/A, 2026-09-16 | 2026-09-14 |
Holding shares or following this stake? See who's behind Tevogen Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Tevogen Inc. and the records around it.
Tevogen Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Watch Tevogen Inc.
Get an email when Tevogen Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tevogen Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Tevogen Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tevogen Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Saadi Ryan H. | 61,705,689 | 3,878 | 1,938,710 | 3,878 | SCHEDULE 13D/A, 2026-11-04 |
| Kirti Desai | 992,983 | 0 | 187,983 | 0 | SCHEDULE 13D/A, 2026-09-16 |
The latest filing identifies Tevogen Inc. by CUSIP 88165K200 and gives its principal executive office as 15 Independence Boulevard, Suite #210, Warren, NJ 07059 (SCHEDULE 13D/A, 2026-11-04).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following: The Reporting Person received a grant of 50,000,000 shares of restricted Common Stock (the "RSA Shares") on November 2, 2026, pursuant to the Restricted Stock Award Agreement (the "RSA Agreement").Saadi Ryan H., SCHEDULE 13D/A, 2026-11-04
Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following: The Reporting Person received a grant of 750,000 shares of restricted Common Stock (the "RSA Shares") on September 14, 2026, pursuant to the Restricted Common Stock Award Agreement (the "RSA Agreement").Kirti Desai, SCHEDULE 13D/A, 2026-09-16
Purpose of Transaction (Item 4)
Saadi Ryan H.
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: The information set forth in Items 3 and 6 of this Amendment is incorporated into this Item 4 by reference.Item 4 of the SCHEDULE 13D/A filed 2026-11-04
Kirti Desai
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: The information set forth in Items 3 and 6 of this Amendment is incorporated into this Item 4 by reference.Item 4 of the SCHEDULE 13D/A filed 2026-09-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-25 | Ryan H. Saadi | 64.5% | SCHEDULE 13D/A |
| 2025-12-16 | Ryan H. Saadi | 62% | SCHEDULE 13D/A |
| 2026-07-14 | Saadi Ryan H. | 59.7% | SCHEDULE 13D/A |
| 2026-09-16 | Kirti Desai | 6.3% | SCHEDULE 13D/A |
| 2026-09-16 | Saadi Ryan H. | 74.4% | SCHEDULE 13D/A |
| 2026-11-04 | Saadi Ryan H. | 91.1% | SCHEDULE 13D/A |
Questions about who owns Tevogen Inc.
Who owns Tevogen Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Tevogen Inc.: Saadi Ryan H. (91.1%, Schedule 13D/A, filed 2026-11-04) and Kirti Desai (6.3%, Schedule 13D/A, filed 2026-09-16).
Who are the largest shareholders of Tevogen Inc.?
By the share each holder's latest filing reports, the largest holders of Tevogen Inc. on this page are Saadi Ryan H. (91.1%) and Kirti Desai (6.3%).
When did Saadi Ryan H. buy into Tevogen Inc.?
The filings give report dates, not purchase dates. The earliest filing from Saadi Ryan H. on this page is the Schedule 13D/A, filed 2026-07-14, reporting 59.7%; its latest, Schedule 13D/A filed 2026-11-04, reports 91.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Tevogen Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Leadership change: Susan Podlogar departs, Director | — | Leadership changes | Source |
| November 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Tevogen Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.